ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,848Medicare Part D Prescriptions Filled, Including Refills

Rank: 239 out of 944

$553K Total Retail Price of All Prescriptions

Rank: 160 out of 944

411 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
30% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Wisconsin
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 411 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

12% of this provider’s 411 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

1% of this provider’s 6,636 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$62 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Wisconsin
OMEPRAZOLE 354 239 1 4
LEVOTHYROXINE SODIUM 318 261 2 2
SIMVASTATIN 242 209 3 1
HYDROCODONE-ACETAMINOPHEN 242 120 S3 3 10
FUROSEMIDE 239 190 5 6
ATORVASTATIN CALCIUM 233 206 6 13
ZOLPIDEM TARTRATE 230 134 7 25
HYDROCHLOROTHIAZIDE 206 190 8 9
WARFARIN SODIUM 202 178 9 7
POTASSIUM CHLORIDE 187 164 10 15
LISINOPRIL 180 147 11 3
ATENOLOL 166 142 12 11
METOPROLOL SUCCINATE 158 133 13 14
AMLODIPINE BESYLATE 156 146 14 5
CRESTOR 149 132 15 28
PRAVASTATIN SODIUM 136 96 16 17
LOSARTAN POTASSIUM 132 129 17 16
TRIAMTERENE-HCTZ 130 112 18 33
METOPROLOL TARTRATE 127 116 19 8
ENALAPRIL MALEATE 123 109 20 43
GABAPENTIN 120 71 21 18
LOVASTATIN 109 104 22 26
METFORMIN HCL 102 76 23 12
ALLOPURINOL 95 67 24 22
BENAZEPRIL HCL 91 79 25 66
CITALOPRAM HBR 89 75 26 19
SYNTHROID 77 77 27 82
SERTRALINE HCL 68 40 28 23
CYCLOBENZAPRINE HCL 65 0 R 29 86
SPIRONOLACTONE 64 48 30 44
PROAIR HFA 62 37 31 56
PANTOPRAZOLE SODIUM 62 45 31 34
TRAMADOL HCL 62 50 31 21
PREDNISONE 61 51 34 32
PLAVIX 60 51 35 55
CLOPIDOGREL 59 46 36 36
PROPRANOLOL HCL 59 59 36 103
PAROXETINE HCL 59 42 36 64
GLIMEPIRIDE 58 41 39 47
TRAZODONE HCL 57 39 40 45
ADVAIR DISKUS 56 37 41 31
FLUTICASONE PROPIONATE 55 39 42 40
CYMBALTA 54 26 43 75
ZETIA 53 39 44 59
GLIPIZIDE 53 42 44 51
OXYCODONE HCL 51 0 S2 46 50
FLUOXETINE HCL 50 45 47 48
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 19, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.